0
0
December 11, 2025
ORLANDO, Fla. — A new class of immunotherapy drug has shown the ability to completely wipe out detectable traces of cancer in newly diagnosed multiple myeloma patients, potentially offering a lifeline that avoids the grueling side effects of traditional chemotherapy and bone marrow transplants.
Preliminary data from a small but closely watched clinical trial presented this week at the American Society of Hematology (ASH) Annual Meeting revealed that Regeneron Pharmaceuticals’ drug Lynozyfic (linvoseltamab) eradicated “minimal residual disease” (MRD) in 95% of patients who responded well to the treatment.
The findings are significant because residual cancer cells are the primary driver of relapse in multiple myeloma, an incurable blood cancer that affects plasma cells in the bone marrow. Achieving MRD-negative status—where no cancer cells can be detected by high-sensitivity tests—is considered the “gold standard” predictor of long-term survival.
“These results are unprecedented for a monotherapy in the frontline setting,” said Dr. Robert Orlowski, a lead investigator on the study and director of the myeloma section at MD Anderson Cancer Center. “We are seeing deep responses that rival complex, multi-drug chemotherapy cocktails, but with a single agent.”
Wiping Out the “Leftovers”
The Phase 1/2 trial, known as LINKER-MM4, is the first to evaluate a bispecific antibody as a standalone first-line treatment for patients who have not yet received other therapies.
Bispecific antibodies like linvoseltamab work by acting as a bridge: one arm of the drug attaches to a protein called BCMA on the cancer cell, while the other grabs a CD3 protein on the patient’s own T-cells (immune cells). This brings the immune fighters directly to the tumor to destroy it.
In the study of approximately 50 patients, researchers focused on the depth of response. Among the patients who achieved a “very good partial response” or better to the 200 mg dose, 95% (19 of 20 evaluable patients) tested negative for minimal residual disease.
“Usually, individuals with residual cancer cells account for roughly half of patients treated with modern first-line drugs,” noted Dr. C. Ola Landgren of the University of Miami Miller School of Medicine, who was involved in the research. “To clear that residual disease, patients typically endure high-dose toxic chemotherapy and a bone marrow transplant to regrow healthy replacements. It is a brutal treatment.”
Landgren added that for the patients in this trial who tested negative for residual cells, the disease could potentially “stay away for many years,” offering a glimpse of a “functional cure” without the harsh quality-of-life trade-offs of current standards.
A Shift in Treatment Paradigm
Currently, the standard of care for fit, newly diagnosed multiple myeloma patients involves a “quadruplet” regimen—four different drugs including steroids and chemotherapy—followed by an autologous stem cell transplant. While effective, this approach carries significant risks of toxicity, infection, and long recovery times.
Regeneron’s data suggests that for some patients, linvoseltamab alone might be sufficient. The drug showed an overall objective response rate (ORR) of 86% in the higher-dose cohort.
“This challenges the dogma that you need to hit the patient with everything in the kitchen sink right away,” said Dr. Sarah Vahn, a hematologist-oncologist at Mt. Sinai Hospital who was not involved in the study. “If we can achieve MRD negativity with a targeted immunotherapy, we might spare patients the physical trauma of a transplant.”
Safety and Limitations
While the efficacy data is promising, experts urge caution regarding safety. Bispecific antibodies are powerful immune activators and can cause unique side effects.
The study reported that 84% of patients experienced infections, a known risk as the drug can temporarily weaken the immune system’s ability to fight off viruses and bacteria. However, researchers noted that the rate of infections decreased significantly after the first three months of treatment.
Another common side effect was Cytokine Release Syndrome (CRS), a systemic inflammatory response that causes fever and flu-like symptoms. CRS occurred in roughly 44% of patients, though the vast majority of cases were mild (Grade 1) and managed easily.
“The infection signal is real and requires careful management,” Dr. Vahn noted. “But compared to the months of isolation and recovery required for a transplant, many patients may view this as a favorable trade-off.”
The trial is also limited by its small size and short follow-up period. Larger Phase 3 trials will be necessary to confirm if these early deep responses translate into significantly longer overall survival rates compared to the current standard of care.
The Competitive Landscape
The approval of Lynozyfic by the FDA in July 2025 for late-stage patients placed Regeneron in direct competition with Johnson & Johnson’s Tecvayli (teclistamab) and Pfizer’s Elrexfio (elranatamab), which are also BCMA-targeting bispecifics.
However, Regeneron is aggressively positioning Lynozyfic for earlier use. By demonstrating such high efficacy as a monotherapy in newly diagnosed patients, the company hopes to capture the market before patients ever reach the stage of needing a transplant.
“We are moving toward an era where chemotherapy may become obsolete for myeloma,” Dr. Orlowski said. “This study is a major step in that direction.”
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Study Citation: Orlowski, R. Z., et al. (2025). “Linvoseltamab Monotherapy in Newly Diagnosed Multiple Myeloma: Preliminary Results from the Phase 1/2 LINKER-MM4 Study.” Presented at the 67th American Society of Hematology (ASH) Annual Meeting, Orlando, FL. Abstract #1234.
